Initial results of a new access device for hemodialysis: Technical Note  by Levin, Nathan W. et al.
Initial results of a new access device for hemodialysis
Technical Note
NATHAN W. LEVIN, PAUL M. YANG, DAVID A. HATCH, ALAN J. DUBROW, NICOLAE S. CARAIANI,
TODD S. ING, VASANT C. GANDHI, ALTHEA ALTO, SYLVIA M. DAVILA, FRANK R. PROSL,
HANS D. POLASCHEGG, and JOSEPH MEGERMAN
Renal Research Institute and Beth Israel Medical Center, New York, New York; Hines VA Hospital, Hines, Illinois; and Biolink
Corporation, Middleboro, Massachusetts, USA
Initial results of a new access device for hemodialysis.
Background. A new subcutaneous device (DIALOCKy) pro-
vides vascular access to patients who currently require hemodial-
ysis (HD). The device consists of a port-like valve, implanted
subcutaneously below the clavicle, which provides a linear flow
passage to two catheters placed in the right atrium via the internal
or external jugular vein. The valve is accessed percutaneously with
needle-cannulas that functionally convert the device to twin
catheters for connecting the patient to the HD lines.
Methods. The device was implanted in 10 outpatients under
local anesthesia. Patients used the device during dialysis 3 times/
week, and data were collected on blood flow, pressures, adverse
events and patient and nurse satisfaction.
Results. The device was used for HD almost immediately
(median 3 days after implantation) and functioned successfully for
more than nine months (mean 6 SD 7.3 6 1.5) in all but one
patient who died of unrelated causes after one month; there were
.800 dialysis sessions total. Blood flows over 300 ml/min were
consistently achieved (average 326 6 40) with venous and arterial
pressures of 200 6 44 and 2246 6 29 mm Hg, respectively. After
66 patient-months, condition of the needle puncture sites re-
mained satisfactory. Five systemic infections occurred in four
patients, producing 2.3 bacteremic episodes per 1000 patient-days.
All resolved without the need for device removal. There were no
infections at the puncture sites. Two patients required fibrin
sheath stripping of their catheters, one whose heparin lock was
not changed for 23 days (for reasons unrelated to the device).
Patient and nurse acceptance was excellent.
Conclusion. The device represents a positive improvement in
the area of HD access.
A large number of patients are dependent on external-
ized catheters for their access to hemodialysis (HD). These
include those awaiting the maturation of a newly created
arterio-venous fistula or the sufficient healing of a freshly
implanted polytetrafluoroethylene (PTFE) graft, and pa-
tients who have no other access sites available due to prior
use, poor vascular anatomy, or compromised cardiac func-
tion. While a number of catheter choices are available for
these patients, none offers a favorable prognosis for more
than 12 months, on average, because of the high incidence
of early failure due to thrombosis and infection [1]. The
silicone catheter, for example, is used widely as both a
bridge device for fistula and graft patients (65% to 80% of
total HD patients) [2] and as a permanent access in 10 to
20% of patients [2, 3] when other modes of access are
either physically impossible or medically contraindicated.
Even in patients with a fistula or graft, 1.6 catheters are
used per HD patient per year on average [4].
The substantial use of catheters, despite their high failure
rate, reflects a major problem in HD access. No new access
devices or methods have been clinically adopted in almost
two decades despite ample descriptions of the failures,
complications and the costly nature of present blood ac-
cesses. Access dysfunction is the most frequent cause of
hospitalization for the ESRD patient [1], comprising one
sixth of all hospitalizations in this population and 2.5 times
the number of hospitalizations for renal failure [2]. The
total cost to the nation’s health care system for diagnosis of
access malfunction, access repair and the treatment of
complication due to access failure is approximately $1.25
billion for 1995 and is growing at a rate of 9% a year.
Frequent access dysfunction and consequent medical inter-
vention, even when successful, adversely affects patient
quality of life.
To address the difficulties with current HD access de-
vices, a new device (Dialocky) based on the concept of the
Vascular Access Port has been developed. The original
Vascular Access Port is a totally implanted subcutaneous
device, which is accessed by percutaneous puncture and has
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an outlet catheter that communicates with the vascular
system [5]. It has been associated with a reduced incidence
of thrombosis and infection (compared to external cathe-
ters) and excellent patient acceptance [6]. It is easy and
convenient to use across medical specialties, and it is
cost-effective [6].
Several devices that comprise ports for hemodialysis
access have been developed previously. Two such ports
were investigated in the U.S. and Europe. They ultimately
failed due to inadequate blood flow, but patients reported
them to be more acceptable than PTFE grafts [7]. Neither,
however, addressed the two major obstacles in using ports
in this capacity, namely: (1) the need for high blood flow
within the device without damage to red cells or activation
of platelets, and (2) the ability to function over many years
without degradation of the sealing mechanism. Modifica-
tions contained in the Dialocky should permit higher blood
flow rates, as required for HD treatment and an increased
product life, compared to the Vascular Access Port [8].
This new design and the subcutaneous placement of the
port should obviate many conditions and factors that
produce the major failures of current access (that is,
clotting and infection).
We describe the first clinical evaluation of the Dialocky
as a chronic hemodialysis access device. Results of an
ongoing pilot study in 10 patients are presented after nine
months of experience with the oldest implant.
METHODS
Dialocky hemodialysis access device
The access port dimensions are approximately 5.1 3
2.9 3 1.3 cm (Fig. 1). The port housing is constructed of
titanium and has two needle-accessible passages. The hous-
ing entrance incorporates a trough-like design intended to
guide the user in accessing the individual needle passages.
A septum-valve assembly within the passage is opened by
the force of the needle insertion, prevents the needle from
inadvertently slipping out of the port and automatically
closes when the needle is withdrawn, thus preventing blood
backflow through the port. A slight narrowing of the inside
wall of the passage stops the access needle from advancing,
preventing damage to catheters or tissue, and cues the user
that the needle is properly “docked” within the passage.
Each passage ends in a nipple connection (outlet tube) that
allows a secure force fit of a customized dialysis catheter.
When the needle is inserted, the entire length of the
passage to the catheter remains one smooth channel with
no sharp edges, gullies, or intrusions. This design feature is
intended to minimize turbulence, hemolysis and platelet
activation during blood flow through the device.
Fig. 1. The Dialocky hemodialysis access device.
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The Dialocky is implanted in a subcutaneous pocket
below the clavicle. Its two catheters are inserted into the
internal or external jugular vein, with their tips placed at
different levels in the right atrium and are then tunneled
from the base of the neck to the subcutaneous pocket. A
plate with suture holes, riveted to the underside of the port
housing, secures the device to fascia within the subcutane-
ous pocket. The riveted connection allows the port housing
to pivot slightly on the suture plate, within the subcutane-
ous pocket and relative to the skin surface, thus allowing
for a wider area of needle puncture sites on the skin
surface.
The dialysis catheters are constructed from medical
grade silicone blended with barium sulfate to render them
radiopaque. They are 40 cm long with an 11 Fr OD and 2.2
mm ID and include a spiral hole pattern at their distal end
typical of many dialysis catheters. Catheters are cut to the
proper length at the time of implantation depending on
individual patient requirements. Centimeter markings on
the catheters assist in determining their final lengths.
At the time of dialysis, the port is accessed by means of
novel needle-cannulas, which pass through the skin and
enable the clinician to functionally use the Dialocky as if it
were a standard twin-luminal catheter (Fig. 2) [9, 10]. Each
single-use cannula consists of a square-tipped 15-gauge
tube attached to silicone rubber tubing fitted with a stan-
dard Luer-lock connector, which provides linkage between
the patient and HD machine. Each cannula is temporarily
converted to a non-coring needle by inserting a mating
stylet, and in combination they sequentially penetrate the
skin with minimum trauma and push open the septum-
valve assembly of the access port. When properly docked
within the port, the cannula hubs external to the skin
interlock to increase the stiffness of the accessed system,
making it less likely that an accidental needle pullout might
occur. Besides providing for access, the needle set allows
for the instillation of a heparin lock within the Dialocky
catheters, preventing clotting between dialysis sessions.
In vitro tests to determine if flow through the Dialocky
causes damage to the blood were performed using a mock
dialysis flow loop and standard measures of lactate dehy-
drogenase (LDH) and potassium release [11]. Results
demonstrated acceptably low levels of hemolysis, that is,
changes in soluble LDH and potassium corresponding to
,4% hemolysis after simulating HD for up to eight hours.
Parallel tests with a standard 16 gauge fistula needle
instead of the Dialocky system yielded up to 7% hemolysis.
Mechanical tests of the Dialocky valve mechanism’s ability
to survive the equivalent of more than five years of access
punctures demonstrated no degradation in its ability to
withstand backflow and pressure. This suggests that a
product life of more than five years without a hardware
failure may be expected, which is substantially longer than
the longevity of current vascular accesses other than the
native fistula. If confirmed for the entire Dialocky system
in vivo, this means that most Dialocky patients might avoid
access emergencies in their lifetime, contrasted with cur-
rent HD patients who average an access complication every
nine months. Animal tests (1 month) confirmed the bio-
compatibility of the device and its repeated accessibility
after subcutaneous implantation.
Fig. 2. Patient’s chest following percutaneous
access of the Dialocky with needle-cannulas.
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Clinical study
In a pilot study, the Dialocky was implanted and utilized
at two sites in the United States, with appropriate Institu-
tional Review Board approval and the patients’ informed
consent. All patients had been prescribed a catheter for
permanent access due to the absence of a viable fistula
(native or prosthetic), and all were in imminent or imme-
diate need of dialysis. All implants were performed during
outpatient procedures under local anesthesia. Patient char-
acteristics and implant dates are listed in Table 1.
After using EMLA® (lidocaine and prilocaine) topical
anesthetic cream for a minimum of 30 minutes [12],
percutaneous access to the Dialocky was achieved using
aseptic technique, with both patient and nurse wearing
masks and caps. With the fluid connections established, 5
ml blood was aspirated into each cannula tubing and
discarded, usually with 3 to 5 cm segments of spaghetti-like
clot having the exact form of the catheter tips. The cannulas
were flushed with saline and then connected to the dialyzer
via standard HD tubing, and dialysis was carried out in the
standard fashion.
Measurements were routinely made of maximum blood
flow, arterial and venous pressures and the times required
to obtain access prior to dialysis and to secure hemostasis
when the Dialocky needles were removed from the skin
after dialysis. At each session, the condition of the skin at
the puncture sites was assessed, and patients were asked to
record their response to the Dialocky by responding (on a
visual analog scale) to questions regarding their level of
comfort and pain during daily activities and sleep, as well as
their level of satisfaction. Each week, nurses were also
asked to evaluate the device, particularly the degree of
difficulty of obtaining access, and to compare it to other
methods for providing hemodialysis access.
RESULTS
Ten patients received Dialocky implants between May
and August 1997. One patient died, within the first month,
of a cardiac event unrelated to her implanted device. After
nine months, the average implant time in the surviving
patients was 7.3 6 1.5 months (mean 6 SD), with 94 6 18
dialysis sessions (range 71 to 113) using the device.
Surgery was uneventful in all cases, and healing of the
implant site occurred without major incident. In most cases
the Dialocky was used within a few days (Table 1), with a
median interval of three days. In several patients, the
presence of a hematoma at the implant site for up to the
first week led to a delay in the Dialock’sy use, in deference
to the patient’s comfort and ability to forego immediate
dialysis. In all cases, the medical staff indicated that the
device could have been used if immediate dialysis had been
necessary and in no case was a catheter used at an
alternative site (such as, femoral vein) to provide tempo-
rary access. In one patient, the Dialocky was implanted
when his creatinine clearance was still around 14 ml/min,
and the use of his implant was delayed for 23 days since
dialysis was not needed during that period. The delay was
not for reasons related to the Dialocky implant, and
dialytic therapy through the device was begun following a
further decline in renal function.
Successful access for hemodialysis was achieved in 818 of
824 total sessions (99.3%) during the nine months following
implantation of the first Dialocky. After an initial training
period of several dialysis sessions, access was typically
accomplished within a minute. Two failures to access
occurred in the first patient to receive a Dialocky. The first
failure occurred during his second session with the Dia-
locky due to the staff’s inexperience in performing the
access procedure. The second failure to access was due to
a contact dermatitis that occurred at the needle puncture
site, after one month of Dialocky use, related to the
patient’s overuse of the EMLA anesthetic cream. Avoid-
ance of EMLA use for 10 days and its more judicious use
thereafter prevented a repeat of this incident. A third
access failure occurred when another patient experienced
unusual swelling following weight lifting exercises. The
remaining failures were related to the presence of “fibrotic
tissue” between the skin and Dialocky needle passage, in
one patient. This tissue impeded passage of the needle
Table 1. Patient characteristics and Dialock™ use
Patient Sex Age Underlying disease Reason for enrollment in study
Date of
implant
First
access Daysa
Dialysis
sessions
1 M 47 Diabetes Inadequate vasculature for access 5-6-97 5-9-97 274 113
2 F 49 Hypertension Fistula not yet available 5-6-97 5-9-97 274 113
3 F 67 Diabetes; hypertension Inadequate vasculature for access 5-29-97 6-5-97 252 106
4 F 64 Polycystic kidney disease; hypertension Inadequate vasculature for access 6-27-97 7-10-97 223 90
5 F 53 Diabetes; hypertension Inadequate vasculature for access 7-22-97 7-23-97 22b 10
6 F 65 Diabetes; hypertension Inadequate vasculature for access 8-11-97 8-12-97 177 76
7 M 45 Hypertension; urate nephropathy Inadequate vasculature for access 8-20-97 8-21-97 169 71
8 M 53 Chronic glomerulonephritis Fistula not yet available 5-19-97 5-27-97 261 106
9 M 68 Diabetes Fistula not yet available 7-14-97 8-6-97 200 73
10 M 39 Glomerulosclerosis Fistula not yet available 8-18-97 8-22-97 170 66
a Up to 2-05-98
b Patient died 8-13-97
Levin et al: A new access device for hemodialysis1742
when the access was attempted, but with additional expe-
rience, nurses were able to avoid the fibrotic area and this
difficulty was no longer a problem. In most cases, the
condition of the skin at the puncture sites was remarkably
good, as judged by the nursing staff. This satisfactory result
may have been helped by the patients’ routine use of aloe
vera cream between dialysis sessions.
Flows measured at each dialysis session for all patients
and averaged on a monthly basis are shown in Figure 3 and
Table 2. The only patient whose flows were below 300
ml/min during his first four months of dialysis had experi-
enced the 23 day delay between implantation and hemodi-
alysis. A fibrin sheath was found to have formed around his
catheter tips, presumably as a result of the failure to
replenish his catheter’s heparin lock. This fibrin sheath was
treated by stripping, using a snare, via a femoral access [3,
13]; this procedure had to be performed three times. The
use of high doses of urokinase within the catheter and
systemically [14] at the time of the third stripping proce-
dure appears to have corrected the problem; this patient’s
blood flow is now consistently over 350 ml/min. One other
patient underwent a single fibrin sheath stripping without
subsequent urokinase treatment. There were no catheter
occlusions.
The dose of dialysis given (Kt/V) has been consistently
over 1.2 (Table 2). Values of hematocrit remain well within
the normal guidelines (Table 2).
Patients were asked to indicate on a visual analog scale
the level of pain and discomfort that they experienced with
the Dialocky. With the exception of some discomfort
during the first week after implantation, in 1 patient, the
average score was ,0.1, that is, negligible, on a scale of 0 to
10. Similar scores were obtained for the Dialock’s interfer-
ence with activities of daily life and during sleep. Regarding
their level of satisfaction with the device, 73% and 27% of
all responses indicated that they were either “very satisfied”
or “satisfied,” respectively; none indicated neutrality or
dissatisfaction. The nurses’ evaluation was similarly posi-
tive, with 72% and 27% responding “very satisfied” and
“satisfied,” respectively, to questions regarding the ease of
access.
Initially, a prolonged time to achieve hemostasis after
removal of the Dialocky cannulas (3 to 6 hr on 4 occasions)
reflected inaccuracies in the manufacturer’s initial recom-
mendation for volumes of heparin to be used in establish-
ing a heparin lock. However, at no time was the amount of
bleeding more than a slow “ooze” that required moderate
compression; patients were not in danger of serious blood
loss. Downward adjustment of this heparin volume was
helpful, but the spilling of heparin into the systemic circu-
lation may continue to occur as a result of mechanical
stimulation of the catheter tips in the right atrium. Further
reductions in the concentration of heparin reduced the
average time of bleeding after cannula removal to just over
five minutes (range of averages for all patients was 2.2 to
6.4 min).
Five infections occurred in four patients (Table 3).
Normalizing the number of bacteremic episodes to the
length of implant time (dividing by the cumulative number
of days of Dialocky implant) yielded an infection rate of 2.3
bacteremias per 1000 patient-days (Fig. 4). This compares
favorably with the recently reported values of 3.9 to 5.1
obtained with standard permanent catheters [15–17]. In
each case, the use of a catheter lock consisting of heparin
combined with antibiotics [18, 19] during the interval
between dialysis sessions, together with systemic antibiotic
therapy resolved the infection. All previously infected
devices were infection-free for 2 to 30 weeks at the end of
the study period (Table 3).
One patient died while on dialysis three weeks after
implantation of the Dialocky, due to an apparent cardiac
event. This 55-year-old patient had a previous history of
diabetes and of myocardial infarction. Blood gas analysis
showed a pO2 of 391 mm Hg and a pCO2 of 9 mm Hg
(during mechanical ventilation), which were consistent with
the absence of pulmonary embolism, and a stable EKG
rhythm made it unlikely that a fatal arrhythmia had oc-
curred. Death was considered to be the result of an
electro-mechanical dissociation, with no relationship be-
tween the patient’s death and use of the access device. No
autopsy was performed.
DISCUSSION
The problems of dialysis access survival are too well
known to be dwelled upon in detail here. The Dialocky
represents a modification of the Vascular Access Port, a
Fig. 3. Monthly averages of maximum blood flow experienced by each
patient from the time of implantation.
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well-proved device for access to the circulation with numer-
ous advantages. Application of hemodynamic principles to
this device permits blood flows suitable for high efficiency
dialysis without damage to red cells. The Dialocky has the
potential for very low thrombosis rates, and its subcutane-
ous position should reduce the potential for infection
compared to catheters. The latter property may also pro-
vide for an improved patient self-image and a better quality
of life due to its cosmetic advantage. The use of the right
atrium for blood source and return makes it impossible for
cardiopulmonary recirculation to occur [20].
During the first nine months of the clinical study re-
ported herein, the device was well accepted by patients and
staff. Access was relatively easier after experience had been
gained, and the problems that occurred did not relate to the
port aspect of device. Post-dialysis bleeding occurred due
to overheparinization, and fibrin sheath formation oc-
curred in two patients and was treated by stripping using a
snare, with follow-up urokinase therapy in one of them.
Infection in four patients was effectively treated without
the need for the device to be removed. In fact, after nine
months all surviving patients continued to receive chronic
hemodialysis, three times a week, through their initial
Dialocky implant. The cumulative infection rate was lower
than what has been reported for permanent catheters,
especially when taking longevity of the device into account.
While not totally free of complications, these early results
suggest that the few problems encountered in using the
Dialocky are manageable and are easily offset by its
consistent ability to support blood flows of over 300 ml/min.
The place of this device in the field of vascular access will
depend on further trials. At present, the experience gained
suggests advantages over internal jugular vein catheters; a
long-term study will be necessary before a relevant com-
parison can be made with synthetic arterio-venous grafts. A
potential application for the device, if current results
persist, would be to safely permit the more complete
maturation of primary arterio-venous fistulas, which often
Table 2. Results for most recent month
Patient
Blood flow
ml/min
Venous
pressure
Pre-pump
arterial pressure
Time to
hemostasis min Kt/V Hematocritb %mm Hga
1 309 6 24 256 6 30 2242 6 9 4.1 6 1.4 1.5 36.0 (30.0)
2 337 6 35 185 6 35 2240 6 13 5.3 6 0.5 1.8 35.0 (25.3)
3 338 6 37 165 6 26 2228 6 17 6.1 6 4.6 2.2 25.9 (18.4)
4 332 6 18 197 6 25 2243 6 7 5.4 6 0.5 2.1 35.1 (28.7)
5 328 6 20 192 6 32 2224 6 17 23.5 6 12.8c — — (34.0)
6 348 6 4 181 6 24 2244 6 8 5.4 6 0.9 1.4 34.1 (32.5)
7 346 6 4 183 6 19 2235 6 9 6.8 6 1.5 1.6 23.8 (25.9)
8 304 6 14 260 6 50 2290 6 34 3.6 6 0.9 1.3 40.8 (32.4)
9 299 6 55 265 6 59 2280 6 51 2.2 6 0.8 1.3 39.7 (33.6)
10 389 6 24 261 6 20 2270 6 28 4.2 6 2.0 1.4 38.4 (36.0)
a Extracorporeal circuit
b Parentheses indicate value at time of entry into study
c First month only (patient died early in study)
Table 3. Treatment of systemic infections
Patient
Date
diagnosed Organism
Probable
source Treatment
Culture
negative
Follow-up
time
weeks
2 6-21-97 E. coli Urinary tract i.v. cefazolin and gentamicin for . 1 week, then
40 mg gentamicin combined with a heparin
lock of 5000 U/ml.
7-8-97 30
8 6-25-97 Staph. epidermidis Puncture site i.v. cefazolin and vancomycin for 4 weeks, then
25 mg vancomycin/ml combined with a
heparin lock of 100 U/ml.
7-28-97 27
9 8-20-97 Propioni bacterium acnes Puncture site i.v. vancomycin, then 100,000 U/ml penicillin G
combined with a heparin lock of 5000 U/ml.
8-28-97 23
8 10-15-97 Staph. epidermidis Puncture site i.v. vancomycin for 2 weeks, then 1 mg/ml
vancomycin combined with a heparin lock of
100 U/ml.
10-31-97 14
1 12-3-97 Staph. capitus Puncture site i.v. vancomycin for 7 weeks, plus 1 mg/ml
vancomycin combined with a heparin lock of
100 U/ml. One dose of 80 mg gentamicin was
given at the start of treatment.
1-21-98 2
a All devices functioning and infection free at the time of this report
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fail when used too early [21]. This could more easily enable
clinicians to fulfill the DOQI guideline of having at least
50% of new dialysis patients obtain their HD access via this
modality [21]. In summary, the new device represents a
major improvement in vascular access for hemodialysis, at
least for those patients who currently depend on external-
ized catheters for temporary access. Evaluation of its
long-term benefits awaits further study.
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